Impel Pharmaceuticals Inc. Common Stock
IMPL
IMPL was delisted on the 15th of December, 2023.
35 hedge funds and large institutions have $99.6M invested in Impel Pharmaceuticals Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 10 reducing their positions, and 10 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
35% more capital invested
Capital invested by funds: $73.9M → $99.6M (+$25.7M)
11.54% more ownership
Funds ownership: 63.9% → 75.44% (+12%)
10% less funds holding
Funds holding: 39 → 35 (-4)
40% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 10
40% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JGC
J. Goldman & Co
New York
|
+$730K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$133K |
| 3 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$52.8K |
| 4 |
Jane Street
New York
|
+$47.9K |
| 5 |
MP
McDonald Partners
Cleveland,
Ohio
|
+$42.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$1.24M |
| 2 |
DA
DCF Advisers
Greenwich,
Connecticut
|
-$522K |
| 3 |
BlackRock
New York
|
-$327K |
| 4 |
Millennium Management
New York
|
-$155K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$128K |
IMPL Hedge Fund Activity: Q4 2022 in Review
35 of the 6,238 institutional investors tracked by Wall St. Rank reported a position in Impel Pharmaceuticals Inc. Common Stock (IMPL) for Q4 2022, worth a combined $99.6M — up 35% from $73.9M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of IMPL and 6 opened new positions — a net loss of 4 holders — while 10 trimmed existing stakes and 6 added.
The largest buyer was J. Goldman & Co, opening a new position worth an estimated $730K. The largest seller was Opaleye Management, exiting entirely with an estimated $1.24M sold.
- 35 institutional investors held Impel Pharmaceuticals Inc. Common Stock (IMPL) as of Q4 2022, down from 39 in Q3 2022.
- Funds reported $99.6M of Impel Pharmaceuticals Inc. Common Stock stock for Q4 2022, up 35% quarter-over-quarter.
- 6 funds opened new Impel Pharmaceuticals Inc. Common Stock positions in Q4 2022 and 10 closed out, a net change of -4 holders.
- The largest Impel Pharmaceuticals Inc. Common Stock buyer in Q4 2022 was J. Goldman & Co, an estimated $730K added.
- The largest Impel Pharmaceuticals Inc. Common Stock seller in Q4 2022 was Opaleye Management, an estimated $1.24M sold.
Based on aggregated 13F filings for Q4 2022.